Top

Published in:

19-07-2022 | Cardiac Amyloidosis | Editorial

Quantitation in ATTR cardiac amyloidosis: the next step is almost there!

Author: Gabriel Blacher Grossman, MD, PhD, FASNC

Published in: Journal of Nuclear Cardiology | Issue 1/2023

Excerpt

Amyloidosis is characterized by the accumulation of pathogenic amyloids, mostly aggregates of misfolded proteins, which are extracellularly deposited in tissues and organs disrupting normal organ function and tissue structure, including the myocardium. The most common among these conditions are ATTR and light-chain amyloidosis (AL). ATTR is most commonly either hereditary (hATTR) or wild type (wtATTR). Transthyretin cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease associated with ATTR; deposits of amyloid protein fibrils in the myocardium cause restrictive cardiomyopathy, degrading both diastolic and systolic cardiac function. …

Gillmore JD, Maurer MS, Falk RH. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.CrossRefPubMed

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari VA. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis. Part 1 of 2—Evidence base and standardized methods of imaging. Circ Cardiovasc Imaging 2021;14:e000029.PubMed

Asif T, Gomez J, Singh V, Doukky R, Nedeltcheva A, Malhotra S. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls. J Nucl Cardiol 2021;28:104‐11.CrossRefPubMed

Masri A, Bukhari S, Ahmad S, et al. Efficient 1-Hour technetium-99m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020;13:e010249.CrossRefPubMedPubMedCentral

Sperry BW, Burgett E, Bybee KA, McGhie AI, O’Keefe JH, Saeed IM, et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol 2020;27:1802‐7.CrossRefPubMed

Avalon JC, Fuqua J, Deskins S, Miller T, Conte J, Martin D, et al. Quantitative single photon emission computed tomography derived standardized uptakes values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis. J Nucl Cardiol 2022. https://doi.org/10.1007/s12350-022-02988-5.CrossRefPubMed

Coelho T, Maurer MS, Suhr OB. THAOS—The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63‐76.CrossRefPubMed

Lousada I, Maurer M, Warner M, Guthrie S, Hsu K, Grogan M. amyloid research consortium cardiac amyloidosis survey. Results from patients with ATTR amyloidosis and their caregivers. Orphanet J Rare Dis 2017;2:7.

Lousada I, Maurer MS, Warne MT, et al. Amyloidosis research consortium cardiac amyloidosis survey: Results from patients with AL and ATTR amyloidosis and their caregivers Heart Failures Society Annual Scientific Meeting. J Card Fail 2019;25:S69.CrossRef

10.

Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail 2022. https://doi.org/10.1002/ejhf.2532.CrossRefPubMed

11.

Mut F, Carvajal I, Camilletti J, Erriest J, Alexanderson E, Grossman GB. Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group. J Nucl Cardiol 2022. https://doi.org/10.1007/s12350-022-03005-5.CrossRefPubMedPubMedCentral

12.

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol 2017;70:466‐77.CrossRefPubMed

13.

Ramsay S, Lindsay K, Fong W, Patford S, Younger J, Atherton J. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in non-affected population. Eur J Hybrid Imaging 2018;2:17.CrossRefPubMed

14.

Ben-Haim S, Chicheportiche A, Goshen E, Arad M, Smekhov M, Menezes LJ, et al. Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis. EJNMMI Res 2021;11:86.CrossRefPubMedPubMedCentral

15.

Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in cardiac amyloidosis: A novel imaging biomarker [published correction appears in JACC Cardiovasc Imaging 2021 Jan, 14(1), pp. 318–319]. JACC Cardiovasc Imaging 2020;13:1353‐63.CrossRefPubMedPubMedCentral

16.

Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S, et al. Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT. J Nucl Med 2021;62:716‐22.CrossRefPubMedPubMedCentral

17.

Bellevre D, Bailliez A, Delelis F, Blaire T, Agostini D, Mouquet F, et al. Quantitation of myocardial ^99mTc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use? J Nucl Cardiol 2022;29:506‐14.CrossRefPubMed

Title: Quantitation in ATTR cardiac amyloidosis: the next step is almost there!
Author: Gabriel Blacher Grossman, MD, PhD, FASNC
Publication date: 19-07-2022
Publisher: Springer International Publishing
Keywords: Cardiac Amyloidosis
Scintigraphy
Amyloidosis
Published in: Journal of Nuclear Cardiology / Issue 1/2023
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-022-03044-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Quantitation in ATTR cardiac amyloidosis: the next step is almost there!

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

The chest pain guidelines revisited: cherry picking from the frequentist tree

Richter's transformation with isolated cardiac involvement diagnosed by 2-[18F]FDG PET/CT scan

Incremental prognostic value of positron emission tomography derived left ventricular mass

Time-related aortic inflammatory response, as assessed with 18F-FDG PET/CT, in patients hospitalized with severely or critical COVID-19: the COVAIR study

Hybrid imaging of neuroendocrine tumors in the heart: Union is strength

Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page